Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

NCT ID: NCT02059967

Last Updated: 2015-03-19

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2015-01-31

Brief Summary

This phase I trial studies the side effects and best dose of image-guided adaptive radiation therapy using active breathing control when given together with chemotherapy and simultaneous integrated boost in treating patients with stage IIA-IIIB non-small cell lung cancer that cannot be removed by surgery. Image-guided adaptive radiation therapy aims radiation therapy right at the tumor so that higher radiation doses can be given without causing bad side effects. Giving these higher doses may help control the tumor better. Breathing causes organs and tissues, including the tumor, to move within the chest. Active breathing control may reduce the volume that needs to be treated. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving image-guided adaptive radiation therapy using active breathing control with chemotherapy and simultaneous integrated boost may be an effective treatment for non-small cell lung cancer.

Detailed Description

OUTLINE: This is a dose-escalation study of IGART.

Patients undergo IGART using active breathing control (ABC) 5 days a week for 7 weeks, for a total of 33 fractions with simultaneous integrated volume adapted boost (SIVAB) during fractions 26-33. Patients also receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.

After completion of study treatment, patients are followed up periodically for 5 years.

Conditions

Adenocarcinoma of the Lung; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)

Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.

Group Type: EXPERIMENTAL

Paclitaxel

Intervention Type: DRUG

Given IV

image-guided adaptive radiation therapy

Intervention Type: RADIATION

Undergo IGART

carboplatin

Intervention Type: DRUG

Given IV

Interventions

Paclitaxel

Given IV

Intervention Type: DRUG

image-guided adaptive radiation therapy

Undergo IGART

Intervention Type: RADIATION

carboplatin

Given IV

Intervention Type: DRUG

Other Intervention Names

5beta,20-epoxy-1,2alpha,4,7beta,10beta, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-4, Anzatax, Asotax, Bristaxol, Praxel, TAX, Taxol, Taxol Konzentrat; IGART, image-guided adaptive radiotherapy; Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA,; Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, platinum, Ribocarbo

Eligibility Criteria

Inclusion Criteria

• Histologically-proven (by biopsy or cytology), unresectable or inoperable lung cancer of the following histologic types: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, non-small cell carcinoma not otherwise specified.
• The tumor stage must be Stage IIA-IIIB (AJCC 7th edition). See http://aboutcancer.com/AJCC 7th lung 1.gif and http://aboutcancer.com/AJCC 7th lung 2.gif for staging.
• All detectable tumor must be encompassed by radiation therapy fields.
• 18-fluorodeoxyglucose PET is required for staging and treatment planning.
• Atelectasis, if present, must involve less than a complete lung.
• Laboratory values:

• Neutrophils >1500/µL
• Platelets >100,000/µL
• Bilirubin < 1.5 mg/dL
• Aspartate aminotransferase (AST; formerly serum glutamic oxaloacetic transaminase [SGOT]) < 2x upper limit normal
• Alanine aminotransferase (ALT; formerly serum glutamic pyruvic transaminase [SGPT]) < 2x upper limit normal
• Serum creatinine < 2.0 mg/dL
• Glomerular filtration rate (GFR) calculated (kidney function test) within 30 days must be ≥ 59 mL/min
• Pulmonary function test (PFT) with FEV-1 ≥ 1.0 L/sec
• Plan of curative radiotherapy with or without concurrent chemotherapy.
• Karnofsky Performance Scale score of ≥ 70%.
• Age ≥ 18 years old.
• Measurable disease on the planning CT.
• Patient must have a completed IMRT plan to 66 Gy in 2 Gy fractions with ≥ 95% of the PTV covered by the prescription dose, and the attending physician must have reviewed and approved the DVHs as follows:

• total lung V20 Gy ≤ 30%
• mean esophageal dose ≤ 34 Gy
• esophageal planning organs-at-risk volume (PRV) V60 Gy ≤ 30%
• heart V40 Gy ≤ 50%
• maximum brachial plexus dose ≤ 66 Gy
• maximum spinal cord PRV dose ≤ 50 Gy
• maximum aorta dose ≤ 66 Gy
• maximum main bronchus dose ≤ 66 Gy
• maximum dose ≥ 66 Gy allowed in only one lobar bronchus.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery.
• Prior radiation therapy to the thorax.
• Previous chemotherapy or previous biologic response modifiers for current lung cancer or within the past 5 years.
• Clinically significant pleural effusions, pericardial effusions, or superior vena cava syndrome.
• Oxygen supplementation required during therapy.
• Involvement of the brachial plexus, or infiltration of the aorta, heart, or esophagus.
• Tumors that affect more than one lobar bronchus, except the second involved bronchus in the right middle lobe bronchus.
• Unable to perform the BH procedures, unless tumor motion is ≤ 3 mm.
• Myocardial infarction within the last 6 months, symptomatic heart disease, uncompensated chronic obstructive pulmonary disease (COPD), or uncontrolled bronchospasms.
• History of a prior malignancy from which the patient has not been disease free for a minimum of 2 years, other than adequately treated basal/squamous skin cancer or in situ cervix cancer or other in situ malignancy.
• Pregnant or lactating women.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Virginia Commonwealth University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elisabeth Weiss, MD

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonwealth University

Other Identifiers

HM20000101

Identifier Type: OTHER

Identifier Source: secondary_id

MCC-20000101

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2014-00163

Identifier Type: REGISTRY

Identifier Source: secondary_id

MCC-13-09209

Identifier Type: -

Identifier Source: org_study_id